JAK2-IN-6 NEW
| Price | $30 | $68 | $108 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: JAK2-IN-6 | CAS No.: 353512-04-6 |
| Purity: 99.64% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | JAK2-IN-6 |
| Description | JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (IC50 at 22.86 μg/mL). Jak2-in-6 inhibits the activity of JAK2 enzymes by interfering with Jak2-related signaling pathways, thereby producing therapeutic effects on the specific disease IN which JAK2 is dysregulated, and does not show activity on JAK1 and JAK3. JAK2 is a protein involved in signaling pathways that regulate cell growth and division. Abnormal activation of JAK2 has been linked to a variety of diseases, including some types of cancer and inflammatory diseases. JAK2-IN-6 has antiproliferative activity against cancer cells. |
| In vitro | The treatment of JAK2-IN-6 (Compound B2; 6.3-50 μg/mL; 48 hours) demonstrates significant antiproliferative activity against PC-9, H1975, and PANC-1 cell lines. The IC50 values for PC-9, H1975, and PANC-1 cell lines are 18.1 μg/mL, 58.3 μg/mL, and 40.6 μg/mL, respectively [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (163.77 mM), Sonication is recommended. |
| Keywords | JAK-2-IN-6 | JAK2IN6 | JAK2 IN 6 | JAK2 |
| Inhibitors Related | Delgocitinib | Ruxolitinib | Atinvicitinib | Tofacitinib Citrate | Resveratrol | 2-(1,8-naphthyridin-2-yl)phenol | Filgotinib | JAK-IN-10 | Tofacitinib | 2,4,5-Trimethoxybenzoic acid | Lentinan | Raspberry ketone glucoside |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Hematonosis Compound Library | JAK-STAT Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3400.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $1.90 |
VIP6Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY